ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0118

Single-cell RNA sequencing of skin reveals vascular dysregulation in antiphospholipid syndrome

Ecem Sevim1, Sumith Panicker2, Gustaf Wigerblad3, Stefania Dell'orso4, Sharon Osgood2, Leslie Castelo-Soccio5, Keisuke Nagao6 and Yogendra Kanthi7, 1NIAMS/NIH, Bethesda, MD, 2NHLBI/NIH, Bethesda, 3National Institutes of Health, Stockholm, Sweden, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 5NIAMS/NIH, Bethesda, 6NIAMS, Bethesda, MD, 7National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD

Meeting: ACR Convergence 2025

Keywords: antiphospholipid syndrome, Gene Expression, skin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0115–0144) Antiphospholipid Syndrome Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune thromboinflammatory disorder defined by persistent antiphospholipid antibodies (aPL) and characterized clinically by macrovascular thrombosis, microvascular disease, and pregnancy morbidity. While aPL-mediated activation of endothelial cells and immune pathways has been established, the molecular drivers of tissue-level vascular dysfunction remain elusive. We performed single-cell RNA sequencing (scRNA-seq) of skin biopsies from patients with APS to identify local cellular and molecular drivers of disease pathogenesis.

Methods: Non-lesional skin biopsies were obtained from the upper thigh of patients with APS (n=6) and healthy controls (n=5). Single-cell suspensions were prepared via enzymatic and mechanical dissociation (Miltenyi Biotec), followed by SYTOX-Green-based FACS for live cell enrichment. Libraries were generated using Chromium Single Cell 5′ HT chemistry (10x Genomics), targeting ~20,000 cells/sample. Sequencing data were processed with Cell Ranger v8.0.1 and analyzed using Seurat v5 in R for QC, integration, clustering, and annotation. Endothelial cells (ECs) were identified by canonical markers (VWF, CDH5, PECAM1); non-ECs (keratinocytes, immune cells, fibroblasts, pericytes, SMCs) were excluded. Differential gene expression and pathway enrichment analyses were performed comparing APS vs. control ECs.

Results: Four patients with APS had a triple-positive aPL profile; phenotypes included microvascular disease (n=2), macrovascular thrombosis (n=1), and one exhibited both. One APS patient was lupus anticoagulant-positive and had macrovascular disease with cardiac valve involvement; and one patient was positive for LA and anti-cardiolipin IgG with a history of macrovascular thrombosis. None of the patients had skin lesions at the time of biopsy.Transcriptomic profiling of skin endothelial cells in APS revealed upregulation of genes involved in glycolysis, response to cytokine stimulus, NF-κB signal transduction, mitochondrial metabolism, cAMP signaling, and VEGF response (ALDOA, PLCG2, NDUFB1, SDF4, PRKAR1A, METAP2, EIF3J). Concurrently, genes related to RAS signaling, endosomal trafficking, chromatin organization, cell migration, endothelial cell development, tube formation, and barrier establishment were downregulated (RASGEF1B, RAPGEF6, RBFOX1, BCOR, ZNF366, RNF7, CTS, THSD7A). These gene expression changes were observed consistently across all six patients with APS compared to healthy controls.

Conclusion: Our single-cell transcriptomic analysis of non-lesional APS skin reveals a metabolically reprogrammed, pro-inflammatory, and stress-responsive endothelial phenotype.Endothelial cells in APS skin demonstrated upregulation of genes associated with activation and inflammatory signaling, alongside downregulation of pathways involved in vascular homeostasis, signaling regulation, and barrier integrity. Together, these findings reveal a consistent transcriptional signature of endothelial dysfunction in APS skin and highlight opportunities to identify tissue-based biomarkers and potential therapeutic strategies targeting endothelial dysfunction in APS.


Disclosures: E. Sevim: None; S. Panicker: None; G. Wigerblad: None; S. Dell'orso: None; S. Osgood: None; L. Castelo-Soccio: None; K. Nagao: None; Y. Kanthi: None.

To cite this abstract in AMA style:

Sevim E, Panicker S, Wigerblad G, Dell'orso S, Osgood S, Castelo-Soccio L, Nagao K, Kanthi Y. Single-cell RNA sequencing of skin reveals vascular dysregulation in antiphospholipid syndrome [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/single-cell-rna-sequencing-of-skin-reveals-vascular-dysregulation-in-antiphospholipid-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/single-cell-rna-sequencing-of-skin-reveals-vascular-dysregulation-in-antiphospholipid-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology